Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients

Figure 2

Viability of T-614 on RASFs in vitro. Cells were treated with the indicated concentrations of T-614 for 72 h. Cell viability was determined by the CCK-8 assay. Values are the mean ± SD for three independent experiments, each in triplicate. ns: not significant, ^∗∗, and ^∗∗∗ versus T-614 (0 μg/mL) alone.